What do systematic reviews say?

Intervention not reported

The review found no eligible studies for this question.

• Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Zinc vs placebo

The review found no eligible studies for this question.

• Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings – denosumab vs placebo

The review found no eligible studies for this question.

• Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings – strontium ranelate vs placebo

The review found no eligible studies for this question.

• Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Bisphosphonates vs placebo or no treatment

It is very uncertain whether summary of findings – bisphosphonates changes adverse effects of treatment compared with placebo or no treatment (very low certainty).

• Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
  OR 15
  2 studies · 143 participants
  Very low

Balneotherapy vs melilotus officinalis

The review found no eligible studies for this question.

• Balneotherapy for chronic venous insufficiency 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Balneotherapy vs dryland exercise

The review found no eligible studies for this question.

• Balneotherapy for chronic venous insufficiency 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Oral plus nebulised antibiotics vs oral antibiotics plus nebulised placebo

Oral plus nebulised antibiotics showed no clear difference in adverse effects of treatment compared with oral antibiotics plus nebulised placebo (low certainty).

• Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis 2022 · Cochrane Headline outcomes only
  OR 3 [0.11, 79.91]
  1 study · 29 participants
  Low

Active treatment vs observation

• Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 45 participants
  Low

Periodontal treatment (subgingival instrumentation, with or without antimicrobials/surgery) vs usual care or no treatment

• Treatment of periodontitis for glycaemic control in people with diabetes mellitus 2022 · Cochrane All outcomes

  3-4 months
  SoF comment: insufficient evidence to determine whether SRP for glycaemic control is associated with any harms; most studies did not evaluate adverse effects. Where reported (e.g. D'Aiuto 2018) serious adverse events…
  Studies not reported
  GRADE not reported

Prophylactic LMWH vs placebo

The review found no eligible studies for this question.

• Treatment for superficial thrombophlebitis of the leg 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Therapeutic LMWH vs placebo

The review found no eligible studies for this question.

• Treatment for superficial thrombophlebitis of the leg 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

NSAIDs vs placebo

The review found no eligible studies for this question.

• Treatment for superficial thrombophlebitis of the leg 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Fondaparinux vs placebo

Fondaparinux showed no clear difference in adverse effects of treatment compared with placebo (moderate certainty).

• Treatment for superficial thrombophlebitis of the leg 2018 · Cochrane Headline outcomes only
  RR 1.13 [0.78, 1.65]
  1 study · 2987 participants
  Moderate

Intervention not reported

The review found no eligible studies for this question.

• Exercise interventions and patient beliefs for people with hip, knee or hip and knee osteoarthritis: a mixed methods… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Zinc supplementation for tinnitus 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Metformin + megestrol vs megestrol

• Metformin for endometrial hyperplasia 2024 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 8 participants
  Very low

Injectional interferon alpha‐2B vs Normal saline

The review found no eligible studies for this question.

• Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Injectional nicardipine vs Normal saline

It is very uncertain whether injectional nicardipine changes treatment‐related adverse effects compared with saline (very low certainty).

• Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
  RR 2.82 [0.12, 66.62]
  1 study · 62 participants
  Very low

Injectional collagenase vs placebo

The review found no eligible studies for this question.

• Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
• Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
  RR 2.32 [1.98, 2.72]
  1 study · 832 participants
  Moderate